MARKET

BTAI

BTAI

BIOXCEL THERAPEU
NASDAQ

Real-time Quotes | Nasdaq Last Sale

45.70
+0.27
+0.59%
After Hours: 45.70 0 0.00% 17:51 12/04 EST
OPEN
45.45
PREV CLOSE
45.43
HIGH
46.03
LOW
44.50
VOLUME
207.68K
TURNOVER
--
52 WEEK HIGH
71.50
52 WEEK LOW
5.58
MARKET CAP
1.11B
P/E (TTM)
-13.5472
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BTAI: Rolling NDA Submission Underway for BXCL501
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update NDA Submission Underway for BXCL501 in Acute Agitation in Schizophrenia and Bipolar Disorder On November 11, 2020, BioXcel Therapeutics, Inc. (BTAI) announced the initiation of a rolling submission of a New Drug Application (NDA) with the U.S. FDA for BXCL501 for treating acute agitation in schizophrenia and
Zacks Small Cap Research · 11/16 14:06
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
BioXcel Therapeutics, Inc. ("BTI" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.
GlobeNewswire · 11/13 12:00
BioXcel Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
GlobeNewswire · 11/13 12:00
BioXcel Therapeutics Q3 EPS $(1.07) Misses $(0.80) Estimate
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.80) by 33.75 percent. This is a 87.72 percent decrease over losses of $(0.57) per share
Benzinga · 11/12 12:16
BioXcel Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Complete NDA submission for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders on track for Q1 2021
GlobeNewswire · 11/12 12:08
BioXcel Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / BioXcel Therapeutics, Inc. (NASDAQ:BTAI) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 8:30 AM Eastern Time.
ACCESSWIRE · 11/12 11:46
BioXcel Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / BioXcel Therapeutics, Inc.
ACCESSWIRE · 11/12 11:45
BioXcel Therapeutics completes pre-NDA meeting with FDA for BXCL501
BioXcel Therapeutics (BTAI) has completed its pre-NDA meeting with the FDA for BXCL501 for the acute treatment of agitation in patients with schizophrenia and bipolar disorders.The purpose of the meeting
Seekingalpha · 11/11 12:59
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BTAI. Analyze the recent business situations of BIOXCEL THERAPEU through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BTAI stock price target is 105.80 with a high estimate of 175.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 137
Institutional Holdings: 11.87M
% Owned: 48.72%
Shares Outstanding: 24.37M
TypeInstitutionsShares
Increased
49
4.97M
New
47
-425.87K
Decreased
20
769.46K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Independent Director
Peter Mueller
President/Chief Executive Officer/Co-Founder/Secretary/Director
Vimal Mehta
Co-Founder/Director
Krishnan Nandabalan
Chief Financial Officer
Richard Steinhart
Executive Vice President
Will Kane
Senior Vice President
Reina Benabou
Chief Scientific Officer
Frank Yocca
Vice President
Robert Risinger
Other
Vincent O'Neill
Vice President - Business Development
Vikas Sharma
Independent Director
Sandeep Laumas
Independent Director
Michal Votruba
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BTAI
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioXcel Therapeutics Inc stock information, including NASDAQ:BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.